Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 18419421.
- Also identified by DOI 10.1086/587989.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.
Medical subject headings
- Biological Therapy
- Information Services
- Mycobacterium Infections
- Opportunistic Infections
- Tumor Necrosis Factor-alpha